US Patent 11466094 Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
Patent 11466094 was granted and assigned to Genentech on October, 2022 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
November 15, 2017
0
Date of Patent
October 11, 2022
0
Patent Applicant
Patent Application Number
15813657
0
Patent Citations Received
Patent Inventor Names
Iraj Hosseini
0
Yu-Waye Chu
0
Saroja Ramanujan
0
Chi-Chung Li
0
Kapil Gadkar
0
Patent Jurisdiction
Patent Number
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11466094 Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
